Validation of the triple a model (age, absolute neutrophil count, absolute lymphocyte count) for the prediction of survival and thrombosis in 1000 patients with polycythemia vera.

IF 2.2 4区 医学 Q3 HEMATOLOGY
Danijela Lekovic, Andrija Bogdanovic, Isidora Arsenovic, Jelena Ivanovic, Mirjana Cvetkovic, Jelica Jovanovic, Nataša Čolović, Marko Lucijanic, Ivan Krečak
{"title":"Validation of the triple a model (age, absolute neutrophil count, absolute lymphocyte count) for the prediction of survival and thrombosis in 1000 patients with polycythemia vera.","authors":"Danijela Lekovic, Andrija Bogdanovic, Isidora Arsenovic, Jelena Ivanovic, Mirjana Cvetkovic, Jelica Jovanovic, Nataša Čolović, Marko Lucijanic, Ivan Krečak","doi":"10.1080/10428194.2025.2503458","DOIUrl":null,"url":null,"abstract":"<p><p>Standard ELN risk stratification for thrombosis and overall survival (OS) in patients with polycythemia vera (PV) is based on advanced age and history of thrombosis. Recently, the triple A (AAA) risk model was developed for OS prediction in patients with essential thrombocythemia, which, besides rising age, incorporates high (≥8x10<sup>9</sup>/L) absolute neutrophil and low(<1.7 × 10<sup>9</sup>/L) lymphocyte counts. The presented multicenter international study on a large cohort of PV patients validated the findings from prior reports and demonstrated excellent prognostic properties of the triple A model with respect to both thrombosis and survival in PV. Moreover, it revealed that the addition of patient comorbidities (assessed through the Charlson comorbidity index (CCI)) to ELN and triple A score may not help to further refine the survival prognostication of these patients. Therefore, the triple A score with its simplicity seems to offer excellent balance during the initial risk assessment in PV, implicating its global applicability.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-11"},"PeriodicalIF":2.2000,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia & Lymphoma","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10428194.2025.2503458","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Standard ELN risk stratification for thrombosis and overall survival (OS) in patients with polycythemia vera (PV) is based on advanced age and history of thrombosis. Recently, the triple A (AAA) risk model was developed for OS prediction in patients with essential thrombocythemia, which, besides rising age, incorporates high (≥8x109/L) absolute neutrophil and low(<1.7 × 109/L) lymphocyte counts. The presented multicenter international study on a large cohort of PV patients validated the findings from prior reports and demonstrated excellent prognostic properties of the triple A model with respect to both thrombosis and survival in PV. Moreover, it revealed that the addition of patient comorbidities (assessed through the Charlson comorbidity index (CCI)) to ELN and triple A score may not help to further refine the survival prognostication of these patients. Therefore, the triple A score with its simplicity seems to offer excellent balance during the initial risk assessment in PV, implicating its global applicability.

验证aaa模型(年龄,绝对中性粒细胞计数,绝对淋巴细胞计数)用于预测1000例真性红细胞增多症患者的生存和血栓形成。
真性红细胞增多症(PV)患者血栓形成和总生存期(OS)的标准ELN风险分层是基于高龄和血栓形成史。最近,AAA风险模型被用于预测原发性血小板增多症患者的OS,除了年龄增加外,还包括高(≥8x109/L)绝对中性粒细胞计数和低(9/L)淋巴细胞计数。这项针对PV患者大队列的多中心国际研究证实了先前报道的发现,并证明了aaa模型在PV血栓形成和生存方面的良好预后特性。此外,研究表明,将患者合并症(通过Charlson合并症指数(CCI)评估)添加到ELN和aaa评分中可能无助于进一步完善这些患者的生存预后。因此,简单的aaa评分似乎在PV的初始风险评估中提供了很好的平衡,暗示其全球适用性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Leukemia & Lymphoma
Leukemia & Lymphoma 医学-血液学
CiteScore
4.10
自引率
3.80%
发文量
384
审稿时长
1.8 months
期刊介绍: Leukemia & Lymphoma in its fourth decade continues to provide an international forum for publication of high quality clinical, translational, and basic science research, and original observations relating to all aspects of hematological malignancies. The scope ranges from clinical and clinico-pathological investigations to fundamental research in disease biology, mechanisms of action of novel agents, development of combination chemotherapy, pharmacology and pharmacogenomics as well as ethics and epidemiology. Submissions of unique clinical observations or confirmatory studies are considered and published as Letters to the Editor
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信